Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

NCT02160626 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Seborrheic Keratosis

Interventions

DRUG: A-101 Vehicle
DRUG: A-101 (40) Topical Solution
DRUG: A-101 (32.5) Topical Solution

Sponsor

Aclaris Therapeutics, Inc.